Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07279493

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Kunming Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT07279493
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07279493. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-22 (actual); primary completion 2026-10-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
Acronym
KPCXM18
Condition
Acute Ischemic Stroke
Intervention (Drug)
The KPCXM18 injection
Intervention (Drug)
Placebo
Intervention (Drug)
The KPCXM18 injection
Lead sponsor
Kunming Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07279493
Content hash
55b2fc933e8dce94e303703c905becdadc4d30f87dc88c8869ee9bb06076b8a6